Associated Papers
Updated global prevalence and ethnic diversity of von Willebrand disease based on population genetics analysis.
Seidizadeh O et al.
Scientific Reports, 2026
41559284 (PubMed )
Supplement: 41598_2026_36145_MOESM1_ESM.pdf
The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants.
Stefanucci L et al.
Blood, 2023
37647632 (PubMed )
Supplement: BLOOD_BLD-2023-020118-mmc3.xlsx › ST3.4
Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases.
Seidizadeh O et al.
Npj Genomic Medicine, 2023
37845247 (PubMed )
Supplement: 41525_2023_375_MOESM1_ESM.pdf
Differential diagnosis of neonatal alloimmune thrombocytopenia: Type 2B von Willebrand disease.
Penel-Page M et al.
Platelets, 2017
Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry.
Sagheer S et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia, 2016
A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.
Veyradier A et al.
Medicine, 2016
Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
Graf L et al.
International Journal of Laboratory Hematology, 2014
Structural basis of regulation of von Willebrand factor binding to glycoprotein Ib.
Blenner MA et al.
The Journal of Biological Chemistry, 2014
Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease.
Chegeni R et al.
Thrombosis Research, 2011
Select a paper to view details